CN1329923A - Concentrated granular medicine for treating baby diarrhea and its preparing process - Google Patents
Concentrated granular medicine for treating baby diarrhea and its preparing process Download PDFInfo
- Publication number
- CN1329923A CN1329923A CN 01106714 CN01106714A CN1329923A CN 1329923 A CN1329923 A CN 1329923A CN 01106714 CN01106714 CN 01106714 CN 01106714 A CN01106714 A CN 01106714A CN 1329923 A CN1329923 A CN 1329923A
- Authority
- CN
- China
- Prior art keywords
- concentrated granular
- infantile diarrhea
- syrup
- treating
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims description 19
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 14
- 235000020357 syrup Nutrition 0.000 claims abstract description 9
- 239000006188 syrup Substances 0.000 claims abstract description 9
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 claims abstract description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 7
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 claims abstract description 7
- 229940036358 bismuth subcarbonate Drugs 0.000 claims abstract description 7
- 229960000304 folic acid Drugs 0.000 claims abstract description 7
- 235000019152 folic acid Nutrition 0.000 claims abstract description 7
- 239000011724 folic acid Substances 0.000 claims abstract description 7
- 108090000790 Enzymes Proteins 0.000 claims abstract description 4
- 102000004190 Enzymes Human genes 0.000 claims abstract description 4
- 229940088598 enzyme Drugs 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 3
- 208000019637 Infantile Diarrhea Diseases 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007779 soft material Substances 0.000 claims description 6
- 239000004382 Amylase Substances 0.000 claims description 5
- 102000013142 Amylases Human genes 0.000 claims description 5
- 108010065511 Amylases Proteins 0.000 claims description 5
- 108010019160 Pancreatin Proteins 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 235000019418 amylase Nutrition 0.000 claims description 5
- 229940055695 pancreatin Drugs 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000576 food coloring agent Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- 235000013599 spices Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 239000002245 particle Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940126589 solid medicine Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A concentrated particle for treating baby's diarrhea, especially the baby's sprue is prepared from 10 raw materials and auxiliaries, such as various enzymes, bismuth subcarbonate, folic acid, etc, through preparing syrup, granulating, drying in hot air and package. Its advantages include low cost, high curative effect and short course of treatment.
Description
The present invention treats the infantile diarrhea concentrated granular and preparation technology belongs to diarrhoea medicine and the preparation technology thereof that special for treating infant abdominal distention, enteritis, intestinal function wadding unrest and dyspepsia cause, relates in particular to a kind of treatment infantile diarrhea novel medicament prescription concentrated granular and preparation technology thereof.
Present domestic pharmacy corporation is produced special for treating children diarrheal preparation seldom, and market sale treatment infantile diarrhea drug formulation is outmoded, mostly is tablet and water preparation, and consumption is indicated not concrete, and the child takes inconvenience, DeGrain.
The present invention treats the infantile diarrhea concentrated granular and preparation technology provides fill a prescription reasonable, the significant new medicament of each prescription complementary action to suffering from the diarrhoea child.Not only craft science is easy for preparation treatment infantile diarrhea concentrated granular, and the codes and standards of temperature when having emphasized among the preparation technology that strict control operation chamber humidity and medicament are dry, noted the code requirement of medicament pH value again, guaranteed the stability of plurality of enzymes composition vigor and other saline crystallization bodies, make each medicine composition reasonable combination, partner treatment, reached gastrointestinal and ruled together, treating both the principal and the secondary aspects of a disease at the same time, the efficacy of a drug rapidly, through sick institute, evident in efficacy, with low cost, have no side effect.Infantile diarrhea is cured in soluble starch, the egg protein that solidifies and casein catapepsis and conversion that children's's stomach and intestinal portion are accumulated rapidly, makes children's's gastrointestinal recover normal digestive function.
In order to realize the foregoing invention purpose, its treatment infantile diarrhea concentrated granular and preparation technology thereof are as described below:
1, treatment infantile diarrhea concentrated granular is made up of pancreatin, pepsin, amylase, bismuth subcarbonate, acetomenadione, folic acid, white cane sugar powder, syrup, starch and food coloring prescription.Treatment infantile diarrhea each prescription of concentrated granular effective prescription amount, effectively degree is as shown in the table:
| The medicine name | Pancreatin | Pepsin | Amylase | Bismuth subcarbonate | Acetomenadione | Folic acid | White sucrose | Syrup 50% | Starch | Food coloring | Add up to |
| Formula ratio (gram) | 1200 | 400 | ?1200 | 3000 | ?20 | ?50 | ?1000 | 2300 | 500 | 330 | 10000 |
| Content (%) | 12.0 | 4.0 | ?12.0 | 30.0 | ?0.2 | ?0.5 | ?10.0 | 23.0 | 5.0 | 3.3 | 100 |
2, the preparation technology of treatment infantile diarrhea concentrated granular is as described below:
(1) with each medicine of prescription respectively weighing get all the ready, it is standby that solid medicine is crossed 80 mesh sieves respectively.
(2) except that syrup, with each prescription element by effective prescription amount assort in oscillating granulator do mix 10 minutes evenly the back add quantitative syrup and make soft material.
(3) soft material is granulated with 18 eye mesh screens, and through heat-wind circulate drying below 45 ℃ to water content below 2%, being distributed into 12 gram pouches is patent medicine.
(4) live for stabilized enzyme, will notice that humidity is controlled in 65% between the chamber when making, temperature can not be above 45 ℃ when dry.
(5) in order to make folic acid keep stable, the soft material pH value must be grasped between 6.0-9.8 when making, and the changeable bismuth subcarbonate makes the soft material pH value obtain adjusting in case of necessity.
Treatment infantile diarrhea concentrated granular instructions of taking: one day three times, each 4 restrained warm boiled water with interior children's in 6 months; 6 months to 1 years old children's, one day three times, each 6 grams, warm boiled water; 1-2 year, one day three times, each 12 grams, warm boiled water; More than 3 years old, one day three times, each 24 grams, warm boiled water.
Diarrhoea is common disease in children; be to cause dyspepsia after improper owing to pediatric diet, the hungry full variable or edible unclean food that goes bad; make starch adhere to gastrointestinal; egg protein solidifies in gastrointestinal; casein stops to transform, and the stimulating intestinal function wadding is random, and enterokinesia is accelerated; moisture content and nutrition can not absorb, and it is external directly to discharge children's.Infant abdominal distention and stool are the primary disease main clinical manifestation as water.Pancreatin, amylase and pepsin in this medicine prescription have the facilitating digestion function, and wherein amylase can make the soluble starch catapepsis, and pepsin can make the egg protein catapepsis of solidifying, and pancreatin can make casein be converted into peptone rapidly and be absorbed.Folic acid is enriched blood, hemopoietic and anti-inflammation and sterilization function, and children's's sprue is had specially good effect.Bismuth subcarbonate has convergence and protective effect for forming the alkali formula carbonate of indefinite bismuth to the intestines and stomach mucosa, can make infant abdominal distention after the gastrointestinal function wadding disorderly recover normal rapidly.Acetomenadione can participate in the liver intravascular coagulation, can prevent after the inflammation of children's's the intestines and stomach hemorrhagely, and loose intestinal smooth muscle is arranged, removes spasm, promotes the effect of moisture absorption, thereby reach the antidiarrheal purpose.White sucrose, syrup and starch not only are this medicine binding, and can make medicine improvement bitterness, increase children's's preference.
Modern pharmacology proves; more than each medicine share; after children's is oral; medicine promptly directly enters each medicine of gastrointestinal organ pipe and has complementary functions; make to accumulate in the gastrointestinal with adherent food body to obtain digestion rapidly, the pathogenic bacteria in the mucus is killed rapidly, and mucosa obtains convergence, pounces on and fill and protect; diarrhoea is stopped, and children's's gastrointestinal function and stool recover normal.
Treatment infantile diarrhea concentrated granular prescription is through long-term clinical application and update, select for use all medicines in syrup, to be mixed, its effective ingredient is concentrated one, form even bonded particulate, compatibility is reasonable, the oral back of children's complementary action is remarkable, can treat infantile diarrhea, particularly treat the infantile diarrhea disease that enteritis, intestinal function wadding unrest and dyspepsia cause, easy to use, effect is obvious, effective percentage reaches 100%, and cure rate reaches 95%, and this children's oral medication diarrhoea concentrated granular is with low cost, the curative effect height, have no side effect, children's's sprue is had specially good effect.
Claims (2)
1; the present invention treats the infantile diarrhea concentrated granular and preparation technology is characterized in that treating the infantile diarrhea concentrated granular by three kinds of enzymes; bismuth subcarbonate; acetomenadione; folic acid and white sucrose; syrup; ten kinds of spice prescriptions of starch and food coloring are formed; the technology of preparation treatment infantile diarrhea concentrated granular is as described below: earlier with various medicines and adjuvant respectively weighing get all the ready; in oscillating granulator, do the mixed syrup that adds after 10 minutes and make soft material; soft material is granulated after heat-wind circulate drying below 45 ℃ with 14 eye mesh screens; after making water content be lower than 2%; be distributed into bag, every bag heavy 12 gram.
2, treatment infantile diarrhea concentrated granular as claimed in claim 1 and preparation technology thereof, it is as follows to it is characterized in that treating the effective degree of each prescription of infantile diarrhea concentrated granular: pancreatin 12.0 pepsin 4.0 amylase 12.0 bismuth subcarbonate 30.0 acetomenadione 0.2 folic acid 0.5 white sucrose 10.0 syrup 23.0 starch 5.0 food colorings 3.3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011067144A CN1150032C (en) | 2001-01-15 | 2001-01-15 | Concentrated granular medicine for treating baby diarrhea and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011067144A CN1150032C (en) | 2001-01-15 | 2001-01-15 | Concentrated granular medicine for treating baby diarrhea and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1329923A true CN1329923A (en) | 2002-01-09 |
| CN1150032C CN1150032C (en) | 2004-05-19 |
Family
ID=4655692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011067144A Expired - Fee Related CN1150032C (en) | 2001-01-15 | 2001-01-15 | Concentrated granular medicine for treating baby diarrhea and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1150032C (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012514604A (en) * | 2009-01-06 | 2012-06-28 | キュレロン リミテッド ライアビリティ カンパニー | Compositions and methods for the treatment or prevention of oral infection by E. coli |
| US8778335B2 (en) | 2000-08-14 | 2014-07-15 | Curemark, Llc | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
| US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
| US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
| US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
| US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
| US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| CN109620809A (en) * | 2019-02-25 | 2019-04-16 | 李潇 | A kind of preparation method of Instant Gefitinib tablet medicament composition |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
-
2001
- 2001-01-15 CN CNB011067144A patent/CN1150032C/en not_active Expired - Fee Related
Cited By (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9624525B2 (en) | 1999-12-17 | 2017-04-18 | Curemark, Llc | Method for treating pervasive development disorders |
| US8815233B2 (en) | 1999-12-17 | 2014-08-26 | Curemark Llc | Method for treating pervasive development disorders |
| US9624526B2 (en) | 1999-12-17 | 2017-04-18 | Curemark Llc | Method for treating pervasive development disorders |
| US8778335B2 (en) | 2000-08-14 | 2014-07-15 | Curemark, Llc | Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
| US9233146B2 (en) | 2000-08-14 | 2016-01-12 | Curemark, Llc | Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders |
| US8921054B2 (en) | 2000-11-16 | 2014-12-30 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US9377459B2 (en) | 2000-11-16 | 2016-06-28 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US10209253B2 (en) | 2000-11-16 | 2019-02-19 | Curemark, Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US11033563B2 (en) | 2005-08-30 | 2021-06-15 | Curemark, Llc | Use of lactulose in the treatment of autism |
| US10350229B2 (en) | 2005-08-30 | 2019-07-16 | Curemark, Llc | Use of lactulose in the treatment of autism |
| US9345721B2 (en) | 2005-08-30 | 2016-05-24 | Curemark, Llc | Use of lactulose in the treatment of autism |
| US11045527B2 (en) | 2008-03-13 | 2021-06-29 | Curemark, Llc | Method of diagnosing preeclampsia or pregnancy-induced hypertension |
| US9023344B2 (en) | 2008-03-13 | 2015-05-05 | Curemark, Llc | Method of treating toxemia |
| US9408895B2 (en) | 2008-03-13 | 2016-08-09 | Curemark, Llc | Method of treating pregnancy-induced hypertension |
| US9925250B2 (en) | 2008-03-13 | 2018-03-27 | Curemark, Llc | Method of treating proteinuria in pregnancy |
| US10272141B2 (en) | 2008-04-18 | 2019-04-30 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
| US9017665B2 (en) | 2008-04-18 | 2015-04-28 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
| US9687534B2 (en) | 2008-04-18 | 2017-06-27 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
| US11235038B2 (en) | 2008-04-18 | 2022-02-01 | Curemark, Llc | Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US10588948B2 (en) | 2008-06-26 | 2020-03-17 | Curemark, Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| US11016104B2 (en) | 2008-07-01 | 2021-05-25 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US10413601B2 (en) | 2008-10-03 | 2019-09-17 | Curemark, Llc | Methods and compositions for the treatment of symptoms of prion diseases |
| US9061033B2 (en) | 2008-10-03 | 2015-06-23 | Curemark Llc | Methods and compositions for the treatment of symptoms of prion diseases |
| US9687535B2 (en) | 2008-10-03 | 2017-06-27 | Curemark, Llc | Methods and compositions for the treatment of symptoms of prion diseases |
| JP2012514604A (en) * | 2009-01-06 | 2012-06-28 | キュレロン リミテッド ライアビリティ カンパニー | Compositions and methods for the treatment or prevention of oral infection by E. coli |
| US9895427B2 (en) | 2009-01-06 | 2018-02-20 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
| US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
| US11357835B2 (en) | 2009-01-06 | 2022-06-14 | Galenagen, Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
| US9084784B2 (en) | 2009-01-06 | 2015-07-21 | Curelon Llc | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces |
| US10736946B2 (en) | 2009-01-06 | 2020-08-11 | Galenagen, Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
| US11419821B2 (en) | 2009-04-13 | 2022-08-23 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
| US10098844B2 (en) | 2009-04-13 | 2018-10-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
| US9931302B2 (en) | 2009-04-13 | 2018-04-03 | Curemark , LLC | Enzyme delivery systems and methods of preparation and use |
| US9415014B2 (en) | 2009-04-13 | 2016-08-16 | Curemark, Llc | Enzyme delivery systems and methods of preparation and use |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| US10716835B2 (en) | 2009-10-21 | 2020-07-21 | Curemark, Llc | Methods and compositions for the prevention and treatment of influenza |
| US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
| US9492515B2 (en) | 2011-04-21 | 2016-11-15 | Curemark, Llc | Method of treatment of schizophreniform disorder |
| US10940187B2 (en) | 2011-04-21 | 2021-03-09 | Curemark, Llc | Method of treatment of schizophreniform disorder |
| US10279016B2 (en) | 2011-04-21 | 2019-05-07 | Curemark, Llc | Method of treatment of schizophreniform disorder |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| US11364287B2 (en) | 2012-05-30 | 2022-06-21 | Curemark, Llc | Methods of treating celiac disease |
| US12226464B2 (en) | 2017-04-10 | 2025-02-18 | Curemark, Llc | Compositions for treating addiction |
| CN109620809A (en) * | 2019-02-25 | 2019-04-16 | 李潇 | A kind of preparation method of Instant Gefitinib tablet medicament composition |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| US12485094B2 (en) | 2020-09-10 | 2025-12-02 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150032C (en) | 2004-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1150032C (en) | Concentrated granular medicine for treating baby diarrhea and its preparing process | |
| CN103638372B (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN102429023B (en) | Milk companion of infant formula milk powder and preparation method thereof | |
| CN102388985A (en) | Formula milk powder | |
| CN107307033A (en) | A kind of biscuit with the aid digestion effect of strengthening the spleen and stomach and preparation method thereof | |
| CN105029393A (en) | Medical formula food for children | |
| CN107334156A (en) | Lactagogue full nutrition formula food | |
| CN103100004A (en) | Pure traditional Chinese medicine preparation infantile malnutrition pills | |
| CN104839670A (en) | Special medical formula food | |
| CN105029402A (en) | Medical formula food for pancreatitis | |
| CN100401920C (en) | Diet fiber composition with intestine-nourishing constipation-releving functions and its production method | |
| CN100521974C (en) | Food | |
| CN102366041B (en) | Nutritional powder suitable for postoperative recuperation of patients | |
| CN101450074A (en) | Composition capable of greatly improving gastrointestinal tract function and preventing and treating astriction | |
| CN117837664A (en) | A kind of alcohol-relieving and liver-protecting compressed candy and preparation method thereof | |
| CN1528352A (en) | Infantile malnutrition pill and preparing method thereof | |
| CN1103761A (en) | Health-care and nutrition infant food | |
| CN101185749B (en) | Navel-applying medicine for treating infantile anorexia | |
| CN118001324B (en) | A compound preparation for preventing and treating poultry enteritis and diarrhea and its preparation method | |
| CN104855999A (en) | Kidney stones non-complete nutritional formula food | |
| CN108669530A (en) | A kind of Hericium erinaceus composition, tablet and preparation method conducive to stomach health | |
| KR20020079609A (en) | Natural foods for improving constipation | |
| CN110420309B (en) | Anti-inflammatory analgesic Tibetan medicine pill for treating chronic appendicitis | |
| CN1174750C (en) | Concentrated granular medicine for treating baby's cough and asthma and its preparing process | |
| CN101147787A (en) | Red glossy ganoderma Chinese medicinal herb composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |